Covenant breach — what actually happens.
A covenant breach feels like the ground opening. In practice it is a defined event with a defined set of responses, and for a solvent business that acts early it is usually a negotiation rather than a crisis. This guide sets out which covenant trips first, what the lender actually does when it does, what a waiver costs, and where the genuine danger sits — so you can tell the difference between a bad quarter and a real problem. It deepens the short answer in our guide to raising debt; if you are already close to a test date, the last section is the one to read first.
Leverage trips first, and cover and cash follow it down.
Most lower-mid-market facilities carry two to four maintenance covenants tested quarterly on a trailing twelve-month basis: a leverage covenant (net debt to EBITDA), an interest-cover or debt-service-cover covenant, sometimes a cashflow-cover covenant, and often a capex limit. When trading softens, the one that trips first is almost always leverage, and the reason is arithmetic. A dip in earnings hits the covenant twice over: EBITDA is the denominator of the leverage ratio and the numerator of every cover ratio, so the same lost profit pushes leverage up and cover down at once. Because leverage is measured against a debt balance that barely moves quarter to quarter, a modest fall in trailing EBITDA moves the ratio sharply.
The practical consequence is that leverage is your early-warning gauge. If you model a soft year, watch the leverage covenant on a rolling twelve-month basis, not against the last audited year, and you will see the breach coming one or two quarters out. That lead time is the single most valuable thing you have, because every good option in this guide depends on acting before the test date rather than after it. A breach you see coming can be managed before the test date; one you first learn of from the compliance certificate is already on the record.
A word on covenant-loose and covenant-lite structures, common on unitranche and other fund debt. A covenant-loose deal carries a single leverage covenant that is only tested when the revolving facility is drawn beyond a set threshold, so if the revolver is undrawn, there may be no maintenance test to breach at all. That offers less reprieve than it sounds. The protections move into the event-of-default and information provisions instead, and a fund lender watches the monthly numbers closely regardless, so a missing covenant is not a missing lender. What it changes is where the conversation starts: differently, and often later, which is not always in the borrower’s favour.
Related reading: what covenants are market, and what to push back on · the covenant that bites first.
The breach happens on the test date, not the day you report it.
A financial covenant is tested as at a quarter-end. You then have a delivery window, typically thirty to sixty days, to submit the compliance certificate that reports the ratios. This matters for timing in a way borrowers routinely miss: the breach crystallises on the test date, so the moment you have the quarter’s management numbers — well before the certificate is due — you know whether you have tripped. The gap between test date and certificate is not a grace period. It is your window to decide how to report, and whether to open a conversation with the lender before the document lands rather than after.
Where the documents provide an equity cure — and in the UK mid-market it would now be unusual to see a leveraged facility without one — there is a defined mechanism to remedy the breach. On a standard Loan Market Association–style provision, the borrower can serve a cure notice within roughly ten business days of the compliance certificate and then has a further ten to fifteen business days to inject the funds, so the cure can complete up to around three months after the test date. That is a real window, but it runs from the test date, not from the day you notice the problem, which is another reason to model the covenant forward rather than wait for the certificate.
The timing convention above follows the standard equity-cure mechanic described by Osborne Clarke and the Association of Corporate Treasurers’ borrower’s guide to the LMA leveraged facilities agreement. Your own documents govern; read the definitions before you rely on any of it.
A breach is a right the lender holds, and rarely one it exercises.
A covenant breach is an event of default, which sounds terminal and is not. It gives the lender the right to act — to charge default interest, to demand repayment, ultimately to enforce security — but it does not compel any of it, and for a business that is still trading and paying interest, a lender that accelerates and enforces almost always recovers less than one that works the situation out. The security a cashflow lender holds, a debenture over the company and a charge over its shares, only bites if the relationship breaks down entirely. On a first breach reported sensibly, enforcement is the last thing on the table, not the first.
What usually happens instead is that the account moves to the bank’s business-support or restructuring team — the unit that handles stressed but viable credits. Being transferred there is unsettling and it is not, in itself, a formal default or a decision to pull the facility; it is a change of who inside the bank manages the relationship, from a relationship director to people who do workouts for a living. As advisers Gateley and Kreston Reeves both put it, whether a breach is waived or escalated turns overwhelmingly on the relationship and on whether the lender has been kept informed. The support team will want a diagnosis, a short-term cash forecast and a credible plan. Give them those early and the unit is a route back to the mainstream book; hand them surprises and it is the antechamber to something worse.
There is evidence that the depth of the lender’s specialist capability shapes the outcome. Research on UK management-buyout lending found that lenders with a dedicated specialist unit were materially more likely to waive a covenant breach and less likely to recall the loan than those without one, precisely because the skills and the reputation for working things out build trust between bank and borrower (Accounting and Business Research). The read-across is that who your lender is, and how they are set up to handle stress, is part of the situation — one more reason a breach conversation benefits from someone who has sat on the lender’s side of it.
Every remedy has a price, and the cheapest is the one you shape.
The common remedies run roughly in order of cost and disruption. A one-off waiver has the lender agree not to act on this particular breach, usually for a fee and often for tightened terms going forward. A reset or amendment loosens the covenant levels for the coming tests, sometimes stepping back up to the original ratios over time as trading recovers, and a related move is simply to suspend a test or two for a quarter or more. An amend-and-extend pushes out the maturity and resets the package in one negotiation, which can be the cleanest answer where the maturity was near anyway. New money from a junior or special-situations lender sits last, for when the gap is a genuine funding hole rather than a covenant that ran ahead of trading — and it is the most expensive capital in the market, right only when the cheaper routes are closed.
The remedies, in rising order of cost and disruption.
First resortLast resort
One-off waiver
The lender agrees not to act on this breach — usually for a fee, often on tightened terms going forward.
Reset or amendment
Covenant levels loosened for the coming tests — or a test suspended — stepping back up as trading recovers.
Amend-and-extend
Maturity pushed out and the package reset in one negotiation — cleanest where the maturity was near anyway.
New money
Junior or special-situations capital for a genuine funding hole — the most expensive capital in the market, right only when cheaper routes are closed.
The equity cure — the remedy the borrower controls.
Where the documents allow one, shareholders inject new equity to cure the test — capped over the life of the loan, and a quarter of headroom rather than a fix.
A waiver or amendment carries a price, and the price is negotiable. A lender will typically look for a waiver or amendment fee, and it may seek a margin uplift, tighter covenants, additional information undertakings, or on fund debt a slice of payment-in-kind interest that rolls onto the balance instead of being paid in cash. The practitioner’s benchmark is that a well-handled amendment fee can often be held to twenty-five basis points or less, especially where the borrower comes with a plan that reduces the lender’s risk rather than merely asking for time (CAPX). The margin uplift is where the real money sits over the life of the facility, so it is worth trading a slightly larger one-off fee for a smaller permanent step-up in the rate. What you give and what you keep is a live negotiation, and it is exactly the kind of thing that reads differently to a lender depending on who is asking.
The equity cure deserves its own note, because it is the remedy the borrower controls. If the documents allow one, shareholders inject new equity or deeply subordinated shareholder debt, and the cash is either applied to prepay senior debt or deemed to increase EBITDA for the covenant test alone, curing the ratio. The catches are all in the fine print: cures are almost always capped over the life of the loan — commonly three or four times in total — and cannot be used in consecutive quarters or more than once or twice in a financial year, with an “over-cure” beyond the amount needed usually disallowed (Osborne Clarke). An equity cure buys a quarter of headroom, not a fix for the business model. Used to bridge a one-off dip it is a clean, borrower-friendly tool; used to paper over a structural decline it postpones the reckoning and spends the shareholders’ money doing it.
A breach forces a refinancing when the terms of the fix are worse than the market.
A single breach, waived and moved past, changes nothing about who funds you. It becomes a refinancing trigger in three situations. The first is when the price of staying is worse than the price of leaving: if the waiver comes with a margin uplift, a heavy fee and covenants tighter than the market would offer a clean credit, a refinancing to another lender can be the cheaper answer, provided the business is genuinely fundable elsewhere. The second is when the breach has knock-on reach through a cross-default clause — a provision that treats a default under one agreement as a default under others. These are near-universal in leveraged lending, and a borrower-friendlier variant, cross-acceleration, only bites once the other lender has actually accelerated, which buys time to cure or negotiate first (Practical Law). Where a covenant breach cross-defaults into other facilities, a comprehensive refinancing may be the only way to draw a line under the whole structure at once.
The third is timing that was already against you. A large band of UK debt written in 2020 and 2021 is maturing across 2026 and 2027, including roughly £25.8bn of CBILS facilities on terms of up to six years, and borrowers are refinancing sub-2%, government-backed money into a market where the Bank of England base rate stands at 3.75% and the effective rate on new SME lending was around 6.11% in early 2026 (Bank of England). A covenant breach on a facility that was going to mature into that repricing anyway is often the moment to run a full process rather than patch the existing deal — you are refinancing regardless, so do it from a position where you still hold options. The one thing that closes those options is delay, because a lender that knows your maturity is weeks away, or that your covenant is already tripped, prices exactly that knowledge in.
The order of play, from the quarter-end to the fix.
The sequence that keeps the most options open is the same every time. As soon as the quarter’s management numbers are in hand — before the compliance certificate is due — model the covenant and confirm whether you have tripped and by how much. If you have, or will, work out your own remedy before you open the conversation: what you are asking for, what you can offer in return, and whether a short-term equity cure is available and worth using. Then approach the lender early, with the diagnosis, a thirteen-week cash forecast and a plan, rather than waiting for the certificate to make the disclosure for you. Flagged early with a remedy attached, a breach stays a conversation; left for the lender to discover, it hardens into a problem, and the difference is almost entirely in the timing.
On who to call first: bring in an adviser before the lender, not after. The person who negotiates the waiver, the reset or the amend-and-extend is doing the highest-leverage work in the whole episode, and the terms of a fix agreed in the first fortnight tend to set the tone for everything that follows. An adviser who has sat on the lender’s side of a business-support conversation knows which asks are routine, which fees are negotiable, and where a credit team will move — and, just as important, can tell you honestly when the right answer is not to fight the covenant but to refinance, take less debt, or in the hardest cases to accept that the business is carrying more leverage than it can support. That is a judgement a lender will never volunteer.
If you have breached, or a test date is coming and the numbers look tight, the first conversation is confidential and without obligation. We will tell you plainly whether this is a bad quarter to be managed or a structure to be refinanced — and which moves keep the most options open. See how a mandate runs, or start below.